Quality of original and biosimilar epoetin products

90Citations
Citations of this article
110Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content, aggregation, isoform profile and potency. Methods: Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta), and two biosimilar products, Binocrit (epoetin alfa) and Retacrit (epoetin zeta), were compared using (1) high performance size exclusion chromatography, (2) ELISA, (3) SDS-PAGE, (4) capillary zone electrophoresis and (5) in-vivo potency. Results: Tested EPO products differed in content, isoform composition, and potency. Conclusion: Of the tested products, the biosimilars have the same or even better quality as the originals. Especially, the potency of originals may significantly differ from the value on the label. © 2010 The Author(s).

Cite

CITATION STYLE

APA

Brinks, V., Hawe, A., Basmeleh, A. H. H., Joachin-Rodriguez, L., Haselberg, R., Somsen, G. W., … Schellekens, H. (2011). Quality of original and biosimilar epoetin products. Pharmaceutical Research, 28(2), 386–393. https://doi.org/10.1007/s11095-010-0288-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free